Company Overview
Company Type: Private Company
Website: www.corealispharma.com
Number of Employees: 42
Year Founded: 2005
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Corealis Pharma, Inc. provides research, development, and manufacturing services for pharmaceutical finished solid dosage forms to pharmaceutical and biotechnology industries. The company offers contract development and manufacturing services for tablets, capsules, and granules. Its services include API characterization; salt selection; pre-formulation; formulation and process development; analytical method development; cGMP stability storage and testing; technical transfer and scale-up; cGMP manufacturing and packaging of phase-I and II clinical trail materials; and technical support for the United States, Europe, and Canadian submissions. Corealis Pharma, Inc. was founded in 2005 and is based in Laval, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 15.8
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 42
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Roy, Yves
President


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
200 boulevard Armand Frappier | Laval, QC | H7V 4A6 | Canada
Phone: 450-973-7505   Fax: 450-973-7506

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
ArchiMed SAS
May-31-2022
Unknown
-
Growth
Caisse de dépôt et placement du Québec
May-31-2022
Unknown
-
Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-31-2022
May-31-2022
Private Placement
Target
Corealis Pharma, Inc.
ArchiMed SAS,Caisse de dépôt et placement du Québec

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-31-2022
Private Placements
Corealis Pharma, Inc. announced that it has received funding from ArchiMed SAS, Caisse de dépôt et placement du Québec
Oct-26-2015
Client Announcements
iCo Therapeutics Inc. Selects Corealis Pharma Inc. for Analytical Development, Formulation Optimization and Scale-Up of the Amphotericin B Oral Delivery System
Sep-19-2012
Company Conference Presentations
Corealis Pharma, Inc. Presents at BioPharm America 2012, Sep-19-2012
Jan-04-2012
Client Announcements
Kedem Pharmaceuticals Engages Corealis Pharma, Inc for the Production of KDM-1102 Clinical Materials
Oct-06-2010
Company Conference Presentations
Corealis Pharma, Inc. Presents at 17th Bio-Contact Quebec Conference, Oct-06-2010


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 09:15 PM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
23
GlobalData

Jun 14, 2023 04:58 AM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
23
GlobalData

Mar 21, 2023 04:21 AM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
23
GlobalData

Dec 13, 2022 05:08 AM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
23
GlobalData

Sep 16, 2022 07:40 PM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
23
GlobalData

Jun 17, 2022 03:16 AM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
23
GlobalData

Mar 17, 2022 04:09 AM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
17
GlobalData

Dec 15, 2021 11:41 PM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
16
GlobalData

Sep 20, 2021 10:01 AM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
10
GlobalData

Jun 21, 2021 08:53 PM
Corealis Pharma, Inc.
Corealis Pharma Inc
Reports
10


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Roy, Yves
President
450-973-7505
450-973-7506
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
